| 2011年
12月31日 | 2012年
12月31日 | 2013年
12月31日 | 2014年
12月31日 | 2015年
12月31日 | 2016年
12月31日 | 2017年
12月31日 | 2018年
12月31日 | 2019年
12月31日 | 2020年
12月31日 | 2021年
12月31日 | 2022年
12月31日 | 2023年
12月31日 |
|---|
| Net loss | -60 | -41 | -56 | -79 | -118 | -176 | -193 | -324 | -254 | -294 | -435 | -482 | -750 |
|---|
| Depreciation | - | - | - | - | - | - | - | 4 | 5 | 9 | 9 | 5 | 6 |
|---|
| Amortization of intangible assets | - | - | - | - | - | - | - | 1 | 5 | 5 | 5 | 5 | 5 |
|---|
| Stock-based compensation expense | 2 | 3 | 9 | 11 | 16 | 18 | 18 | 26 | 27 | 36 | 46 | 58 | 75 |
|---|
| Loss on extinguishment of debt | - | - | - | - | - | - | - | -2 | - | - | -18 | - | - |
|---|
| Amortization of debt issuance costs | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 | - | 4 | 7 |
|---|
| Accretion Expense | - | - | 0 | 0 | 0 | 0 | 1 | 0 | - | - | - | - | - |
|---|
| Paid-in-Kind Interest | - | - | - | - | - | - | - | - | - | - | - | 4 | 23 |
|---|
| Other Noncash Expense | - | - | - | - | - | - | - | - | - | - | - | 4 | 19 |
|---|
| Finance lease amortization expense | - | - | - | - | - | - | - | - | 0 | 1 | 1 | 2 | 3 |
|---|
| Accretion of discount on marketable securities, net | - | - | - | - | - | - | - | - | - | - | - | - | 9 |
|---|
| Noncash Operating Lease Expense | - | - | - | - | - | - | - | - | 10 | 6 | 13 | 12 | 9 |
|---|
| Finance lease amortization expense | - | - | - | - | - | - | - | - | 0 | 1 | 1 | 2 | 3 |
|---|
| Change in fair value of deferred and contingent consideration liabilities | - | - | - | - | - | - | - | - | - | - | 7 | -21 | 29 |
|---|
| Noncash Operating Lease Expense | - | - | - | - | - | - | - | - | 10 | 6 | 13 | 12 | 9 |
|---|
| Change in fair value of interest rate swap | - | - | - | - | - | - | - | - | - | - | - | -2 | 0 |
|---|
| Change in fair value of deferred and contingent consideration liabilities | - | - | - | - | - | - | - | - | - | - | 7 | -21 | 29 |
|---|
| Accounts receivable | 0 | -1 | - | - | - | - | - | 6 | 14 | -3 | 8 | 6 | 12 |
|---|
| Inventory | - | - | - | - | - | - | - | 7 | 21 | 21 | 17 | 2 | 14 |
|---|
| Prepaid expenses and other current assets | 0 | 0 | 2 | 3 | 1 | -0 | 3 | 6 | 9 | 3 | 6 | -3 | -2 |
|---|
| Other assets | - | - | - | - | - | - | - | - | 16 | 6 | 24 | 25 | 20 |
|---|
| Increase (Decrease) in Accounts Payable | 1 | 5 | -1 | 3 | -2 | 3 | 4 | 4 | -5 | 30 | -8 | 50 | 15 |
|---|
| Other liabilities | - | - | - | - | - | - | - | - | - | - | 5 | -13 | -11 |
|---|
| Net cash used in operating activities | -30 | -31 | - | - | - | - | -160 | -258 | -251 | -219 | -363 | -400 | -536 |
|---|
| Change in fair value of interest rate swap | - | - | - | - | - | - | - | - | - | - | - | -2 | 0 |
|---|
| Vertuis Bio, Inc. | - | - | - | - | - | - | - | - | - | - | - | - | 10 |
|---|
| Adrestia Therapeutics Ltd | - | - | - | - | - | - | - | - | - | - | - | - | 76 |
|---|
| Vertuis Bio, Inc. | - | - | - | - | - | - | - | - | - | - | - | - | 10 |
|---|
| Adrestia Therapeutics Ltd | - | - | - | - | - | - | - | - | - | - | - | - | 76 |
|---|
| Accounts receivable | 0 | -1 | - | - | - | - | - | 6 | 14 | -3 | 8 | 6 | 12 |
|---|
| Inventory | - | - | - | - | - | - | - | 7 | 21 | 21 | 17 | 2 | 14 |
|---|
| Prepaid expenses and other current assets | 0 | 0 | 2 | 3 | 1 | -0 | 3 | 6 | 9 | 3 | 6 | -3 | -2 |
|---|
| Other assets | - | - | - | - | - | - | - | - | 16 | 6 | 24 | 25 | 20 |
|---|
| Increase (Decrease) in Accounts Payable | 1 | 5 | -1 | 3 | -2 | 3 | 4 | 4 | -5 | 30 | -8 | 50 | 15 |
|---|
| Other liabilities | - | - | - | - | - | - | - | - | - | - | 5 | -13 | -11 |
|---|
| Net cash used in operating activities | -30 | -31 | - | - | - | - | -160 | -258 | -251 | -219 | -363 | -400 | -536 |
|---|
| Net loss | -60 | -41 | -56 | -79 | -118 | -176 | -193 | -324 | -254 | -294 | -435 | -482 | -750 |
|---|
| Depreciation | - | - | - | - | - | - | - | 4 | 5 | 9 | 9 | 5 | 6 |
|---|
| Amortization of intangible assets | - | - | - | - | - | - | - | 1 | 5 | 5 | 5 | 5 | 5 |
|---|
| Stock-based compensation expense | 2 | 3 | 9 | 11 | 16 | 18 | 18 | 26 | 27 | 36 | 46 | 58 | 75 |
|---|
| Loss on extinguishment of debt | - | - | - | - | - | - | - | -2 | - | - | -18 | - | - |
|---|
| Amortization of debt issuance costs | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 | - | 4 | 7 |
|---|
| Accretion Expense | - | - | 0 | 0 | 0 | 0 | 1 | 0 | - | - | - | - | - |
|---|
| Paid-in-Kind Interest | - | - | - | - | - | - | - | - | - | - | - | 4 | 23 |
|---|
| Other Noncash Expense | - | - | - | - | - | - | - | - | - | - | - | 4 | 19 |
|---|
| Finance lease amortization expense | - | - | - | - | - | - | - | - | 0 | 1 | 1 | 2 | 3 |
|---|
| Accretion of discount on marketable securities, net | - | - | - | - | - | - | - | - | - | - | - | - | 9 |
|---|
| Noncash Operating Lease Expense | - | - | - | - | - | - | - | - | 10 | 6 | 13 | 12 | 9 |
|---|
| Finance lease amortization expense | - | - | - | - | - | - | - | - | 0 | 1 | 1 | 2 | 3 |
|---|
| Change in fair value of deferred and contingent consideration liabilities | - | - | - | - | - | - | - | - | - | - | 7 | -21 | 29 |
|---|
| Noncash Operating Lease Expense | - | - | - | - | - | - | - | - | 10 | 6 | 13 | 12 | 9 |
|---|
| Change in fair value of interest rate swap | - | - | - | - | - | - | - | - | - | - | - | -2 | 0 |
|---|
| Change in fair value of deferred and contingent consideration liabilities | - | - | - | - | - | - | - | - | - | - | 7 | -21 | 29 |
|---|
| Accounts receivable | 0 | -1 | - | - | - | - | - | 6 | 14 | -3 | 8 | 6 | 12 |
|---|
| Inventory | - | - | - | - | - | - | - | 7 | 21 | 21 | 17 | 2 | 14 |
|---|
| Prepaid expenses and other current assets | 0 | 0 | 2 | 3 | 1 | -0 | 3 | 6 | 9 | 3 | 6 | -3 | -2 |
|---|
| Other assets | - | - | - | - | - | - | - | - | 16 | 6 | 24 | 25 | 20 |
|---|
| Increase (Decrease) in Accounts Payable | 1 | 5 | -1 | 3 | -2 | 3 | 4 | 4 | -5 | 30 | -8 | 50 | 15 |
|---|
| Other liabilities | - | - | - | - | - | - | - | - | - | - | 5 | -13 | -11 |
|---|
| Net cash used in operating activities | -30 | -31 | - | - | - | - | -160 | -258 | -251 | -219 | -363 | -400 | -536 |
|---|
| Change in fair value of interest rate swap | - | - | - | - | - | - | - | - | - | - | - | -2 | 0 |
|---|
| Vertuis Bio, Inc. | - | - | - | - | - | - | - | - | - | - | - | - | 10 |
|---|
| Adrestia Therapeutics Ltd | - | - | - | - | - | - | - | - | - | - | - | - | 76 |
|---|
| Vertuis Bio, Inc. | - | - | - | - | - | - | - | - | - | - | - | - | 10 |
|---|
| Adrestia Therapeutics Ltd | - | - | - | - | - | - | - | - | - | - | - | - | 76 |
|---|
| Accounts receivable | 0 | -1 | - | - | - | - | - | 6 | 14 | -3 | 8 | 6 | 12 |
|---|
| Inventory | - | - | - | - | - | - | - | 7 | 21 | 21 | 17 | 2 | 14 |
|---|
| Prepaid expenses and other current assets | 0 | 0 | 2 | 3 | 1 | -0 | 3 | 6 | 9 | 3 | 6 | -3 | -2 |
|---|
| Other assets | - | - | - | - | - | - | - | - | 16 | 6 | 24 | 25 | 20 |
|---|
| Increase (Decrease) in Accounts Payable | 1 | 5 | -1 | 3 | -2 | 3 | 4 | 4 | -5 | 30 | -8 | 50 | 15 |
|---|
| Other liabilities | - | - | - | - | - | - | - | - | - | - | 5 | -13 | -11 |
|---|
| Net cash used in operating activities | -30 | -31 | - | - | - | - | -160 | -258 | -251 | -219 | -363 | -400 | -536 |
|---|
| Purchase of fixed assets | 1 | 0 | 1 | 5 | 3 | 4 | 3 | 13 | 42 | 6 | 7 | 10 | 13 |
|---|
| Purchase of marketable securities | - | - | - | - | - | - | - | - | - | - | 50 | 100 | 589 |
|---|
| Maturities of marketable securities | - | - | - | - | - | - | - | - | - | - | - | 75 | 375 |
|---|
| Cash acquired in asset acquisition | - | - | - | - | - | - | - | - | - | - | - | - | 3 |
|---|
| Cash paid for Business Acquisition, net | - | - | - | - | - | - | - | - | - | - | 7 | - | - |
|---|
| Maturities of marketable securities | - | - | - | - | - | - | - | - | - | - | - | 75 | 375 |
|---|
| PARI milestone upon regulatory approvals | - | - | - | - | - | - | - | 2 | - | 1 | - | - | - |
|---|
| Cash paid for Business Acquisition, net | - | - | - | - | - | - | - | - | - | - | 7 | - | - |
|---|
| Net cash used in investing activities | 34 | 62 | - | - | - | - | -3 | -15 | -42 | -7 | -64 | -35 | -224 |
|---|
| Proceeds from Stock Options Exercised | - | 0 | 2 | 1 | 5 | 1 | 3 | 9 | 20 | 26 | 22 | 20 | 18 |
|---|
| Proceeds from Issuance of Common Stock | 0 | 26 | 67 | 109 | 223 | - | 378 | - | 261 | 246 | 270 | 292 | 152 |
|---|
| Payment on extinguishment of 1.75% convertible senior notes due 2025 | - | - | - | - | - | - | - | 3 | - | - | 13 | - | - |
|---|
| Payment of principal of 1.75% convertible senior notes due 2025 | - | - | - | - | - | - | - | - | - | - | 225 | - | - |
|---|
| Proceeds from Convertible Debt | - | - | - | - | - | - | - | 450 | - | - | 575 | - | - |
|---|
| Proceeds from issuance of Term Loan | - | - | - | - | - | - | - | - | - | - | - | 350 | - |
|---|
| Proceeds From Royalty Financing | - | - | - | - | - | - | - | - | - | - | - | 150 | - |
|---|
| Payment of debt issuance costs | - | 0 | 0 | 0 | 0 | 0 | - | 14 | - | - | 16 | 18 | 1 |
|---|
| Other financing activities | - | - | - | - | - | - | - | - | - | - | -1 | -1 | - |
|---|
| Payments of finance lease principal | - | - | - | - | - | - | - | - | - | 1 | - | - | 1 |
|---|
| Net cash provided by financing activities | -0 | 45 | - | - | - | - | 381 | 387 | 285 | 271 | 613 | 793 | 168 |
|---|
| Effect of exchange rates on cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | -1 | -1 | -0 |
|---|
| Net (decrease) increase in cash and cash equivalents | - | - | - | - | - | - | - | - | -8 | 45 | 184 | 357 | -592 |
|---|
| Cash paid for interest | - | - | - | - | - | - | - | 6 | 8 | 9 | 11 | 10 | 36 |
|---|
| Income Taxes Paid, Net | - | - | 1 | 9 | 3 | -0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
|---|
| Purchase of fixed assets | 1 | 0 | 1 | 5 | 3 | 4 | 3 | 13 | 42 | 6 | 7 | 10 | 13 |
|---|
| Purchase of marketable securities | - | - | - | - | - | - | - | - | - | - | 50 | 100 | 589 |
|---|
| Maturities of marketable securities | - | - | - | - | - | - | - | - | - | - | - | 75 | 375 |
|---|
| Cash acquired in asset acquisition | - | - | - | - | - | - | - | - | - | - | - | - | 3 |
|---|
| Cash paid for Business Acquisition, net | - | - | - | - | - | - | - | - | - | - | 7 | - | - |
|---|
| Maturities of marketable securities | - | - | - | - | - | - | - | - | - | - | - | 75 | 375 |
|---|
| PARI milestone upon regulatory approvals | - | - | - | - | - | - | - | 2 | - | 1 | - | - | - |
|---|
| Cash paid for Business Acquisition, net | - | - | - | - | - | - | - | - | - | - | 7 | - | - |
|---|
| Net cash used in investing activities | 34 | 62 | - | - | - | - | -3 | -15 | -42 | -7 | -64 | -35 | -224 |
|---|
| Proceeds from Stock Options Exercised | - | 0 | 2 | 1 | 5 | 1 | 3 | 9 | 20 | 26 | 22 | 20 | 18 |
|---|
| Proceeds from Issuance of Common Stock | 0 | 26 | 67 | 109 | 223 | - | 378 | - | 261 | 246 | 270 | 292 | 152 |
|---|
| Payment on extinguishment of 1.75% convertible senior notes due 2025 | - | - | - | - | - | - | - | 3 | - | - | 13 | - | - |
|---|
| Payment of principal of 1.75% convertible senior notes due 2025 | - | - | - | - | - | - | - | - | - | - | 225 | - | - |
|---|
| Proceeds from Convertible Debt | - | - | - | - | - | - | - | 450 | - | - | 575 | - | - |
|---|
| Proceeds from issuance of Term Loan | - | - | - | - | - | - | - | - | - | - | - | 350 | - |
|---|
| Proceeds From Royalty Financing | - | - | - | - | - | - | - | - | - | - | - | 150 | - |
|---|
| Payment of debt issuance costs | - | 0 | 0 | 0 | 0 | 0 | - | 14 | - | - | 16 | 18 | 1 |
|---|
| Other financing activities | - | - | - | - | - | - | - | - | - | - | -1 | -1 | - |
|---|
| Payments of finance lease principal | - | - | - | - | - | - | - | - | - | 1 | - | - | 1 |
|---|
| Net cash provided by financing activities | -0 | 45 | - | - | - | - | 381 | 387 | 285 | 271 | 613 | 793 | 168 |
|---|
| Effect of exchange rates on cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | -1 | -1 | -0 |
|---|
| Net (decrease) increase in cash and cash equivalents | - | - | - | - | - | - | - | - | -8 | 45 | 184 | 357 | -592 |
|---|
| Cash paid for interest | - | - | - | - | - | - | - | 6 | 8 | 9 | 11 | 10 | 36 |
|---|
| Income Taxes Paid, Net | - | - | 1 | 9 | 3 | -0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
|---|